^
    13d
    Diagnostic and treatment challenges associated with the atypical presentation of ALK-positive anaplastic large cell lymphoma in a Jehovah's Witness patient. (PubMed, BMJ Case Rep)
    Despite a transient response, the disease progressed rapidly. This case underscores the importance of a broad differential diagnosis, judicious use of advanced diagnostics and individualised treatment planning, particularly in rare and aggressive lymphoproliferative disorders.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    21d
    T-prolymphocytic leukemia with three distinct immunophenotypic subsets. (PubMed, Virchows Arch)
    This brief report describes a patient with T-PLL in whom three distinct abnormal T-cell subsets were delineated by flow cytometric analysis using TRBC1. This case illustrates striking intratumoral heterogeneity in a neoplasm that is typically regarded as phenotypically uniform and demonstrates the utility of TRBC1 analysis in refining diagnostic assessment.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • TCL1A (TCL1 Family AKT Coactivator A)
    26d
    Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Feb 2027 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1)
    |
    MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • cyclosporin A microemulsion
    1m
    Splenic B-Cell Lymphoma/Leukemia With TCL1 Gene Rearrangement. (PubMed, Int J Lab Hematol)
    The identification of IGH::TCL1 fusion in these two cases of splenic B-cell lymphoma/leukemia suggests that TCL1 gene rearrangements can occur in B-cell lymphoma/leukemia and should not be considered exclusive to T-cell prolymphocytic leukemia. Accurate diagnosis of splenic B-cell lymphoma/leukemia with TCL1 rearrangement requires evaluation of morphologic and immunophenotypic features and genetic assessment of TCL1.
    Journal
    |
    CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • TCL1A (TCL1 Family AKT Coactivator A)
    1m
    Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (clinicaltrials.gov)
    P2, N=60, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Jan 2028 --> Mar 2029 | Trial primary completion date: Feb 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • Neupogen (filgrastim)
    2ms
    A Unique Case of Concomitant T-Prolymphocytic Leukemia and B-Cell Acute Lymphoblastic Leukemia. (PubMed, EJHaem)
    One proposed mechanism for the development of both hematologic malignancies in this patient is the acquisition of a KMT2A rearrangement, raising the possibility of clonal evolution resulting in therapy-related or secondary leukemia. Another explanation is the presence of a common clonal stem cell progenitor harboring a JAK3 mutation.
    Journal
    |
    KMT2A (Lysine Methyltransferase 2A) • JAK3 (Janus Kinase 3)
    |
    KMT2A rearrangement
    |
    Campath (alemtuzumab)
    2ms
    Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov)
    P=N/A, N=153, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Valcyte (valganciclovir)
    3ms
    Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia. (PubMed, Blood Neoplasia)
    Continued studies evaluating JAK inhibitors in patients with T-PLL are warranted. This trial was registered at www.clinicaltrials.gov as #NCT03989466.
    Clinical • P1 data • Journal
    |
    JAK3 (Janus Kinase 3) • STAT5B (Signal Transducer And Activator Of Transcription 5B) • TCL1A (TCL1 Family AKT Coactivator A) • IL2RG (Interleukin 2 Receptor Subunit Gamma)
    |
    Campath (alemtuzumab) • itacitinib (INCB039110)
    3ms
    Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia (clinicaltrials.gov)
    P1/2, N=36, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Jakafi (ruxolitinib)
    4ms
    Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL (clinicaltrials.gov)
    P2, N=41, Completed, Ohio State University Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> May 2025 | Trial primary completion date: Aug 2025 --> May 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • lenalidomide • Monjuvi (tafasitamab-cxix)
    4ms
    NCI-2018-00315: Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • pevonedistat (MLN4924)